vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $18.7M, roughly 1.2× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -5.3%, a 4.4% gap on every dollar of revenue. On growth, BGSF, INC. posted the faster year-over-year revenue change (-9.4% vs -25.7%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-15.8M). Over the past eight quarters, BGSF, INC.'s revenue compounded faster (-5.3% CAGR vs -15.9%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BGSF vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $18.7M |
| Net Profit | $-1.2M | $-154.0K |
| Gross Margin | 35.0% | — |
| Operating Margin | -17.6% | -6.9% |
| Net Margin | -5.3% | -0.8% |
| Revenue YoY | -9.4% | -25.7% |
| Net Profit YoY | -18.2% | 97.6% |
| EPS (diluted) | $-0.12 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | — | ||
| Q3 25 | $26.9M | — | ||
| Q2 25 | $23.5M | $18.7M | ||
| Q1 25 | $20.9M | $50.9M | ||
| Q4 24 | $24.3M | $38.1M | ||
| Q3 24 | $29.8M | $33.4M | ||
| Q2 24 | $25.7M | $25.1M | ||
| Q1 24 | $24.5M | $41.5M |
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-5.8M | — | ||
| Q2 25 | $-3.7M | $-154.0K | ||
| Q1 25 | $-722.0K | $23.5M | ||
| Q4 24 | $-981.0K | $18.9M | ||
| Q3 24 | $-804.0K | $5.7M | ||
| Q2 24 | $-761.0K | $-6.5M | ||
| Q1 24 | $-792.0K | $13.8M |
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | — | ||
| Q3 25 | -3.5% | — | ||
| Q2 25 | -18.8% | -6.9% | ||
| Q1 25 | 1.6% | 44.4% | ||
| Q4 24 | -15.7% | 46.4% | ||
| Q3 24 | -3.4% | 12.3% | ||
| Q2 24 | -5.7% | -33.7% | ||
| Q1 24 | 1.7% | 28.1% |
| Q4 25 | -5.3% | — | ||
| Q3 25 | -21.6% | — | ||
| Q2 25 | -15.9% | -0.8% | ||
| Q1 25 | -3.5% | 46.2% | ||
| Q4 24 | -4.0% | 49.6% | ||
| Q3 24 | -2.7% | 17.2% | ||
| Q2 24 | -3.0% | -26.0% | ||
| Q1 24 | -3.2% | 33.3% |
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.52 | — | ||
| Q2 25 | $-0.34 | — | ||
| Q1 25 | $-0.06 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $119.9M |
| Total Assets | $57.8M | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $41.2M | — | ||
| Q2 25 | $2.8M | $49.0M | ||
| Q1 25 | $2.0M | $47.6M | ||
| Q4 24 | $32.0K | $38.1M | ||
| Q3 24 | $262 | $40.6M | ||
| Q2 24 | $226 | $43.2M | ||
| Q1 24 | $50 | $36.2M |
| Q4 25 | $48.1M | — | ||
| Q3 25 | $50.7M | — | ||
| Q2 25 | $78.3M | $119.9M | ||
| Q1 25 | $81.8M | $25.0M | ||
| Q4 24 | $82.3M | $-456.0K | ||
| Q3 24 | $82.9M | $-23.5M | ||
| Q2 24 | $83.2M | $-31.2M | ||
| Q1 24 | $83.6M | $-31.7M |
| Q4 25 | $57.8M | — | ||
| Q3 25 | $83.6M | — | ||
| Q2 25 | $149.7M | $175.1M | ||
| Q1 25 | $152.3M | $98.5M | ||
| Q4 24 | $150.1M | $120.5M | ||
| Q3 24 | $157.3K | $139.0M | ||
| Q2 24 | $159.8K | $159.2M | ||
| Q1 24 | $170.6K | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-15.8M |
| Free Cash FlowOCF − Capex | $1.7M | $-15.8M |
| FCF MarginFCF / Revenue | 7.6% | -84.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.8M | — | ||
| Q2 25 | $2.2M | $-15.8M | ||
| Q1 25 | $1.1M | $-21.0M | ||
| Q4 24 | $3.2M | $-19.9M | ||
| Q3 24 | $6.5M | $-20.7M | ||
| Q2 24 | $7.3M | $-19.5M | ||
| Q1 24 | $7.4M | $-26.0M |
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $2.1M | $-15.8M | ||
| Q1 25 | $1.0M | $-21.2M | ||
| Q4 24 | $2.5M | $-20.0M | ||
| Q3 24 | $6.5M | $-20.7M | ||
| Q2 24 | $7.3M | $-19.6M | ||
| Q1 24 | $6.9M | $-26.2M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -18.1% | — | ||
| Q2 25 | 9.1% | -84.6% | ||
| Q1 25 | 5.0% | -41.6% | ||
| Q4 24 | 10.2% | -52.5% | ||
| Q3 24 | 21.7% | -62.1% | ||
| Q2 24 | 28.5% | -78.2% | ||
| Q1 24 | 28.1% | -63.1% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 3.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 2.0% | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
